New Maintenance Treatment for Acute Myeloid Leukemia Prolongs the Lives of Patients

This article originally appeared in the WCM Newsroom.

Patients with acute myeloid leukemia (AML), the most common form of acute leukemia in adults, that has gone into remission following initial chemotherapy remain in remission longer and have improved overall survival when they are given a pill form of the cancer drug azacitidine as a maintenance treatment, according to a randomized, international phase 3 clinical trial for which Weill Cornell Medicine and NewYork-Presbyterian are trial sites. This is the first time a maintenance treatment for AML has shown such a strong benefit for patients, and it is already being adopted as part of standard care.

Read more in the WCM Newsroom.

In This Article

Clinical Service